Figure 2.

Resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) levels at different stages of KD in patients with and without coronary artery lesions (CALs). KD-I, acute stage; KD-II, afebrile stage; KD-III, subacute stage.

Qi et al. Arthritis Research & Therapy 2012 14:R251   doi:10.1186/ar4094
Download authors' original image